Why Did PolyPid Plunge 10.12% Despite Positive Trial Results?

On June 10, 2025, PolyPid's stock experienced a significant drop of 10.12% in pre-market trading.

Analysts from H.C. Wainwright have raised their price target for PolyPid to $13 from $11, maintaining a Buy rating on the shares. This adjustment reflects the company's promising developments and strategic initiatives.

Roth Capital has initiated coverage on PolyPid with a Buy rating and a $9 price target, highlighting the company's potential in the market. This bullish sentiment is supported by the successful Phase 3 trial results of D-PLEX100, which demonstrated a 58% reduction in surgical site infections.

The positive Phase 3 trial results for D-PLEX100 have been a significant driver for PolyPid's stock. The trial met all key secondary efficacy endpoints, showcasing the drug's effectiveness in preventing surgical site infections. This success positions D-PLEX100 as a strategic asset in addressing unmet medical needs, particularly in the surgical infection prevention sector.